Thursday 27 September 2018 |
| 07:30-20:30 | | Registration
|
| 08:00-10:00 | | ESPE Working Group on Disorders of Sex Development (DSD) & Turner Syndrome (TS) Chair(s): Tülay Güran (Istanbul, Turkey), Malcolm Donaldson (Glasgow, UK), Rodolfo Rey (Buenos Aires, Argentina) & Christina Kanaka-Gantenbein (Athens, Greece) ESPE DSD and TS Joint Meeting: Common ground of DSD and TS Christos Lambrakis Hall
|
| 08:00 | | Introduction |
| 08:03 | | Session 1: Mixed gonadal dysgenesis |
| 08:05 | WG1.1 | Longterm outcome in males with 45,X/46,XY mosaicism |
| 08:25 | WG1.2 | The 45X/46XY gonad and similar variants – characteristics and risk of malignancies |
| 08:50 | | Session 2: Introduction |
| 08:52 | WG1.3 | Congenital heart defects and cardiovascular risk in individuals who have a 45X/46XY karyotype |
| 09:20 | WG1.4 | Condition-specific tools for transition care multidisciplinary programs: lessons from the Turner syndrome models |
| 09:45 | WG1.5 | DSD News: I-DSD, I-CAH; DSDnet, Endo-ERN |
| 09:52 | WG1.6 | TS News |
| 09:59 | | Closing Remarks |
| 08:00-10:00 | | ESPE Working Group on Obesity Chair(s): Jesús Argente (Madrid, Spain) & Tatyana Chaychenko (Kharkiv, Ukraine) Lessons of metabolism in childhood obesity Dimitris Mitropoulos Hall
|
| 08:00 | WG2.1 | Body shapes - growth phenotypes in obese children |
| 08:30 | WG2.2 | Impaired fasting glycaemia in pediatric obesity and type 2 diabetes in young adulthood |
| 09:00 | WG2.3 | Less Prenatal and/or More Postnatal Weight Gain: a Highway to PCOS |
| 09:30 | WG2.4 | Effects of the fetal-neonatal environment on later metabolism. |
| 08:00-10:00 | | ESPE Working Group on Bone and Growth Plate (BGP) Chair(s): Ola Nilsson (Stockholm, Sweden), Oliver Semler (Cologne, Germany) A Concise Update from the European Reference Networks & BGP case studies Alexandra Trianti Hall
|
| 08:05 | WG3.1 | Assessment of fracture risk in children |
| 08:35 | WG3.2 | SHOX – from gene to growth plate |
| 09:10 | WG3.3 | Complex Clinical Presentations: Case Study 1:Dysosteosclerosis: Phenotypic and Genetic Heterogeneity |
| 09:25 | WG3.4 | Complex Clinical Presentations: Case Study 2: - A case of severe osteoporosis in a child with myasthenia gravis; remarkable improvement after treatment with rituximab |
| 09:40 | WG3.5 | Update on EndoERN |
| 09:50 | WG3.6 | Update on BOND |
| 08:00-10:00 | | ESPE Working Group on Diabetes Technology (DT) Chair(s): Moshe Phillip (Petah Tikva, Israel) & Tadej Battelino (Ljubljana, Slovenia) Digital Clinics Banqueting Hall
|
| 08:00 | WG4.1 | Introduction |
| 08:05 | WG4.2 | How do we run our diabetes centers: University Children's Hospital, University Medical Centre Ljubljana (Slovenia) and Schneider Children's Medical Center (Israel) |
| 08:25 | WG4.3 | Use of Apps for Physical activity in type 1 diabetes |
| 08:45 | WG4.4 | The future role of machine learning and computer vision in carbohydrate estimation for patients with diabetes |
| 09:05 | WG4.5 | Analyzing and Reporting of Sensor Glucose Levels |
| 09:25 | WG4.6 | Updates on the developments of Decision Support Systems for the treatment of diabetes |
| 09:45 | WG4.7 | Use of social media for improving glucose control in patients with type 1 diabetes |
| 08:00-10:00 | | Working Group: Paediatric and Adolescent Gynaecology (PAG) Chair(s): Anne-Simone Parent (Liège, Belgium) & Abel López-Bermejo (Girona, Spain) Understanding the mechanisms related to pubertal onset and progression as well as the consequences of early puberty Nikos Skalkotas Hall
|
| 08:00 | WG5.1 | Prenatal Programming of PCOS: interplay between anti-müllerian hormone and the GnRH system |
| 08:25 | WG5.2 | Genetic determinants of puberty timing |
| 08:45 | WG5.3 | Body adiposity as a determinant of age at puberty |
| 09:10 | WG5.4 | Endocrine-metabolic outcome of women with a history of sexual precocity |
| 09:30 | WG5.5 | Neurodevelopment and puberty |
| 08:00-10:00 | | Working Group: Gender Dysphoria Chair(s): Gary Butler (London, UK) Non-binary gender indentification & fertility in transgender adolescents MC3
|
| 08:00 | | Section 1: Non-binary gender identification; Social and endocrine management challenges |
| 08:05 | WG6.1 | Gender identity development: Neither male nor female or being both, growing up as gender queer |
| 08:30 | | Endocrine challenges in adolescents with non-binary gender identification. |
| 09:00 | | Section 2: Fertility in transgender adolescents |
| 09:05 | WG6.2 | Current options for fertility conservation in trans-teenagers |
| 09:30 | WG6.3 | Fertility preservation in transgender adolescents: an ethical perspective. Is the sky the limit? |
| 08:00-10:00 | | Global Pediatric Endocrinology and Diabetes (GPED) The art of pediatric endocrine testing: Assessing the needs of low-resource settings MC2
|
| 08:00 | | Introduction |
| 08:05 | | The 2018 World Health Organization Model List of Essential In Vitro Diagnostics |
| 08:25 | | Diagnostic Endocrine Tests in Egypt and Indonesia: Opportunities and Obstacles |
| 09:05 | | The WHO Model Lists of Essential Medicines and of In Vitro Diagnostics: Two Sides of the Same Coin? |
| 09:25 | | Round Table |
| 10:00-10:30 | | Refreshment Break, Posters & Exhibition
|
| 10:30-10:45 | | Opening Ceremony Christos Lambrakis Hall
|
| 10:45-11:15 | | Plenary 1 Chair(s): Peter Clayton (Manchester, UK) & Anita Hokken-Koelega (Rotterdam, The Netherlands) Christos Lambrakis Hall
|
| 10:45 | PL1 | Oncofertility: From Bench to Bedside to Babies |
| 11:15-11:45 | | ESPE AWARDS Chair(s): Mehul T Dattani (London, UK) Henning Andersen Prizes Supported by Novo Nordisk Christos Lambrakis Hall
|
| 12:00-13:30 | | Special Symposium: Nutrition and Growth Chair(s): Moshe Phillip (Petah Tikva, Israel) & Jan-Maarten Wit (Leiden, Holland) Nikos Skalkotas Hall
|
| 12:00 | SS1.1 | It is not just the growth hormone axis |
| 12:30 | SS1.2 | Fascinating growth phenomena: what causes individual catch-up growth and population secular change |
| 13:00 | SS1.3 | Interaction between nutrition, the endocrine system and the growth plate |
| 12:00-13:30 | | Symposium 1 Chair(s): Roland Pfäffle (Leipzig, Germany) & Rachel Reynaud (Marseille, France) Recent developments in the understanding of Hypothalamo-pituitary disorders Dimitris Mitropoulos Hall
|
| 12:00 | S1.1 | The molecular basis of Combined Pituitary Hormone Deficiency: lessons from animal models |
| 12:30 | S1.2 | Stem Cells in the Pituitary: a role for regeneration? |
| 13:00 | S1.3 | A novel role for Vasopressin in parenting |
| 12:00-13:30 | | Symposium 2 Chair(s): Christina Kanaka-Gantenbein (Athens, Greece) & Reiko Horikawa (Tokyo, Japan) Gonads/DSD Banqueting Hall
|
| 12:00 | S2.1 | The biology of germ cell tumors in Disorders of Sex Development |
| 12:30 | S2.2 | Disruption of testicular development and function |
| 13:00 | S2.3 | Assessing gonadal function |
| 12:00-13:30 | | Symposium 3 Chair(s): Asma Deeb (Abu Dhabi, UAE) & Agnès Linglart (Paris, France) Recent Consensus Guidelines Christos Lambrakis Hall
|
| 12:00 | S3.1 | Silver-Russell Syndrome |
| 12:20 | S3.2 | Hypogonadotrophic Hypogonadism |
| 12:40 | S3.3 | Paediatric Obesity |
| 13:00 | S3.4 | Prevention and Management of Rickets |
| 12:00-13:30 | | Controversy 1 Chair(s): Stefano Cianfarani (Rome, Italy) Should growth hormone be used in iSS? Alexandra Trianti Hall
|
| 12:00 | CON1.1 | PRO - Should Growth Hormone be used in iSS? |
| 12:45 | CON1.2 | AGAINST - Should Growth Hormone be used in iSS? |
| 13:30-15:00 | | Lunch, Posters & Exhibition
|
| 14:00-15:00 | | Satellite Symposia Alexandra Trianti Hall
|
| 15:00-16:00 | | Free Communications 1 Chair(s): Svetlana Lajic (Stockholm, Sweden) & Stefan Wudy (Giessen, Germany) Adrenals and HPA Axis Christos Lambrakis Hall
|
| 15:00 | FC1.1 | A novel non-invasive Short Synacthen Test validated in a healthy paediatric population. |
| 15:10 | FC1.2 | Long-term effects of prenatal dexamethasone treatment and postnatal glucocorticoid treatment on brain structure in the context of CAH. |
| 15:20 | FC1.3 | Targetting the binding of ACTH to the Melanocortin receptor by structure modeling and design of peptide antagonists to block excess androgens in 21-hydroxylase deficiency. |
| 15:30 | FC1.4 | Whole Exome Sequencing in patients with Primary Generalized Glucocorticoid Resistance identifies a novel TRIM28 gene mutation (p.R230X). |
| 15:40 | FC1.5 | Untargeted Plasma Metabolomics in Subjects with Differences in Tissue Glucocorticoid Sensitivity Identifies a Novel Metabolic Signature. |
| 15:50 | FC1.6 | A novel stem cell model for the Triple A Syndrome. |
| 15:00-16:00 | | Free Communications 2 Chair(s): Nick Shaw (Birmingham, UK) & Lars Sävendahl (Stockholm, Sweden) Bone, growth plate and mineral metabolism 1 Banqueting hall
|
| 15:00 | FC2.1 | Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody, for X-Linked Hypophosphatemia (XLH): Sustained Improvement in Two Phase 2 Trials in Affected Children 1-12 Years Old. |
| 15:10 | FC2.2 | Whole genome sequencing reveals novel intragenic deletions of GNAS as causes of pseudohypoparathyroidism type 1a. |
| 15:20 | FC2.3 | Clinical course of hypoparathyroidism in patients with APECED (APS1) |
| 15:30 | FC2.4 | Diagnostic Performance of Artificial Neural Network-Based TW3 Skeletal Maturity Assessment. |
| 15:40 | FC2.5 | Radial ESWT stimulates longitudinal bone growth in cultured rat fetal metatarsal bones. |
| 15:50 | FC2.6 | Final Height is Negatively Related to Disease Burden in Mitochondrial Disease. |
| 15:00-16:00 | | Free Communications 3 Chair(s): Hilary Hoey (Ireland) and Thomas Reinehr (Datteln, Germany) Diabetes and Insulin Session 1 Dimitris Mitropoulos
|
| 15:00 | FC3.1 | Neonatal diabetes owned to potassium channel mutation: response to sulfonylureas according to the genotype. |
| 15:10 | FC3.2 | Genome-Wide Meta-Analysis identifies a novel low frequency STK39 variant of large effect on risk of Type 1 Diabetes. |
| 15:20 | FC3.3 | Pediatric patients with type 1 diabetes and abnormal nerve conduction studies demonstrate higher neopterin levels: potential role as a biochemical marker for peripheral neuropathy. |
| 15:30 | FC3.4 | Is the glycaemic response from fat in meals dose dependent in children and adolescents with T1DM on intensive insulin therapy? |
| 15:40 | FC3.5 | Genotype and Phenotype Correlation in Syndromic Forms of Hyperinsulinaemic Hypoglycaemia – a 10-year follow-up study in a tertiary centre. |
| 15:50 | FC3.6 | Using CRISPR/Cas9gene editing to study the molecular genetics of Congenital Hyperinsulinism. |
| 15:00-16:00 | | Free Communications 4 Chair(s): Feyza Darendeliler (Istanbul, Turkey) & Bradley Miller (Minnesota, USA) GH and IGFs Nikos Skalkotas
|
| 15:00 | FC4.1 | Monogenic and digenic gene mutations are present in children with idiopathic short stature (ISS). |
| 15:10 | FC4.2 | Effects of IGF-1R nuclear localization in glioblastoma cells. |
| 15:20 | FC4.3 | The reduction in longitudinal growth induced by PAPP-A2 deficiency is associated with reduced body weight, increased energy expenditure and behavior modification. |
| 15:30 | FC4.4 | A Cross-sectional Study of IGF-I Bioavailability through Childhood and Associations with PAPP-A2, STC2 and Anthropometric Data. |
| 15:40 | FC4.5 | Prediction of adult height by artificial intelligence (AI) through machine learning (ML) from early height data. |
| 15:50 | FC4.6 | Absorption and Excretion of Somapacitan, a Long-Acting Growth Hormone (GH) Derivative. |
| 15:00-16:00 | | Free Communications 5 Chair(s): Johnny Deladoey (Montreal, Canada) & Paul Von Trotsenberg (Amsterdam, The Netherlands) Thyroid MC3
|
| 15:00 | FC5.1 | Beta1-Tubulin Gene (TUBB1) Mutations Cause Thyroid Dysgenesis Associated to Abnormal Platelet Morphology and Hyper-aggregation. |
| 15:10 | FC5.2 | Enrichment of inherited rare variants in non-syndromic congenital hypothyroidism from thyroid dysgenesis identified by exome sequencing: the contribution of IKBKE to vasculogenesis and thyroid development. |
| 15:20 | FC5.3 | Computational analysis of the ligand binding domain of the thyroid hormone receptor for the rational design of an efficient protein-based biosensor for the detection of thyroid hormone disrupting chemicals. |
| 15:30 | FC5.4 | Thyroid hormone analog therapy in patients with MCT8 deficiency: the Triac Trial. |
| 15:40 | FC5.5 | Guidelines for the Management of Paediatric Differentiated Thyroid Carcinoma; a UK endeavour. |
| 15:50 | FC5.6 | Alterations in DNA methylation status of gene promoters in children and adolescents with autoimmune thyroid disease. |
| 15:00-16:00 | | How do I... Chair(s): Nils Krone (Sheffield, UK) Session 1 Alexandra Trianti Hall
|
| 15:00 | HDI1.1 | …Interpret a low Vit D concentration? |
| 15:20 | HDI1.2 | …Differentiate between constitutional delay in growth and puberty and hypog hypog? |
| 15:40 | HDI1.3 | ...Manage an adolescent with Type 1 diabetes and microalbuminuria |
| 16:00-16:30 | | Rapid Free Communications 1 Chair(s): Svetlana Lajic (Stockholm, Sweden) & Stefan Wudy (Giessen, Germany) Adrenals and HPA axis Christos Lambrakis Hall
|
| 16:00 | RFC1.1 | The relative contributions of genetic and environmental factors on cortisol metabolism at pre-, mid- and post-pubertal ages. |
| 16:05 | RFC1.2 | Changes in CYP19A1 and CYP3A4 activities due to population genetic variations in human P450 Oxidoreductase. |
| 16:10 | RFC1.3 | Sphingosine-1-phosphate lyase (SGPL1) deficiency is associated with mitochondrial dysfunction. |
| 16:15 | RFC1.4 | Mass spectrometry-based assessment of childhood androgen excess in 487 consecutive patients over 5 years. |
| 16:20 | RFC1.5 | Quantitative urinary GC-MS based steroid analysis for treatment monitoring of adolescents and young adults with autoimmune primary adrenal insufficiency. |
| 16:25 | RFC1.6 | A laboratory harmonization strategy for steroid hormone profiling by MoM-transformed, normalized reference ranges independent of age-, sex -and units. |
| 16:00-16:30 | | Rapid Free Communications 2 Chair(s): Nick Shaw (Birmingham, UK) Bone, growth plate and mineral metabolism 1 Banqueting hall
|
| 16:00 | RFC2.1 | High-resolution MRI Imaging Of Bone-Muscle-Fat In Glucocorticoid Treated Boys With Duchenne Muscular Dystrophy: Results from the ScOT-DMD study. |
| 16:05 | RFC2.2 | S-25OHD is Associated with Hand Grip Strength and Myopathy at Five Years in Girls: An Odense Child Cohort Study. |
| 16:10 | RFC2.3 | Measured free 25-hydroxyvitamin D in healthy children and relationship to total 25-hydroxyvitamin D, calculated free 25-hydroxyvitamin D and vitamin D binding protein. |
| 16:15 | RFC2.4 | Novel severe skeletal dysplasia with under-mineralisation associated with reduced in utero calcium transport and TRPV6 compound heterozygous variants. |
| 16:20 | RFC2.5 | Identification of characteristic neurological complications in infants with Achondroplasia by routine MRI screening. |
| 16:25 | RFC2.6 | The novel R211Q POP1 homozygous mutation causes severe short stature but uniquely only subtle skeletal dysplasia. |
| 16:00-16:30 | | Rapid Free Communications 3 Diabetes and Insulin Session 1 Dimitris Mitropoulos
|
| 16:00 | RFC3.1 | Diagnostics of early atherosclerosis risk in Kids (DEAR-Kids): Retinal vessel analysis in pediatric type 1 diabetes – Retinal arteriolar narrowing caused by high HbA1c. |
| 16:05 | RFC3.2 | Personalized and predictive medicine for pediatric diabetes through a genetic test using next generation sequencing. |
| 16:10 | RFC3.3 | Significant prevalence of severe monogenic immune defects among children with Type 1 diabetes and low T1D-genetic risk score. |
| 16:15 | RFC3.4 | Functional characterization of a novel KLF11 mutation identified in a family with autoantibody-negative type 1 diabetes. |
| 16:20 | RFC3.5 | Recent secular change in pre- and postnatal growth and adiposity in Infants of Mothers with Gestational Diabetes. |
| 16:25 | RFC3.6 | Treatment adherence and weight loss are key predictors of HbA1c one year after diagnosis of childhood Type 2 Diabetes in UK. |
| 16:00-16:30 | | Rapid Free Communications 4 Chair(s): Feyza Darendeliler (Istanbul, Turkey) & Bradley Miller (Minnesota, USA) GH and IGFs Nikos Skalkotas
|
| 16:00 | RFC4.1 | Metabolomic changes in patients with PAPP-A2 deficiency in response to rhIGF1 treatment. |
| 16:05 | RFC4.2 | Data mining and computational analysis of human growth hormone gene (GH1) sequence in normal population to identify potential variants with disease-causing effects. |
| 16:10 | RFC4.3 | A deletion encompassing exon 2 of the alsgene: Analysis of a patient with ALS deficiency and his family. |
| 16:15 | RFC4.4 | A longitudinal study on miRNAs circulating levels in a cohort of SGA and AGA subjects, evaluated during childhood and young adulthood. |
| 16:20 | RFC4.5 | 12-Month effects of once-weekly and twice-monthly administration of hybrid Fc-fused human growth hormone, GX-H9, treatment in pediatric with GHD deficiency. |
| 16:25 | RFC4.6 | Effect of 2 years of Growth Hormone Treatment on Glucose Tolerance in Adults with Prader-Willi Syndrome. |
| 16:00-16:30 | | Rapid Free Communications 5 Chair(s): Johnny Deladoey (Gatineau, Canada) & Paul Van Trotsenberg (Amsterdam, The Netherlands) Thyroid MC3
|
| 16:00 | RFC5.1 | Serum levels of the soluble receptor for advanced glycation end productsare reduced in chrildren with Hashimoto's Thyroiditis. |
| 16:05 | RFC5.2 | Analysis of chosen polymorphisms rs7138803 A/G - FAIM2, rs7093069 C/T - IL-2RA, rs5742909 C/T - CTLA-4 in pathogenesis of Hashimoto's thyroiditis in children. |
| 16:10 | RFC5.3 | Incidence and treatment outcome of childhood thyrotoxicosis. |
| 16:15 | RFC5.4 | The value of cytological, histological and US examination to determine of management children with nodular goiter. |
| 16:20 | RFC5.5 | Evidence for a founder effect in Multiple Endocrine Neoplasia 2. |
| 16:25 | RFC5.6 | DUOX2 Deficiency in Quebec: From Life-threatening Compressive Goiter in Infancy to Lifelong Euthyroidism. |
| 16:30-16:45 | | Refreshment Break, Posters & Exhibition
|
| 16:45-17:15 | | Plenary 2. Chair(s): Mehul T Dattani (London, UK) & George Chrousos (Athens, Greece) Christos Lambrakis Hall
|
| 16:45 | PL2 | Oxytocin and the healing power of love |
| 17:15-18:15 | | Meet The Expert 1 Dimitris Mitropoulos Hall
|
| 17:15 | MTE1.1 | The role of Radiology in the diagnosis of skeletal dysplasias |
| 17:15-18:15 | | Meet The Expert 2 Nikos Skalkotas Hall
|
| 17:15 | MTE2.1 | Endocrine complications in Thalassemia |
| 17:15-18:15 | | Meet The Expert 3 Banqueting Hall
|
| 17:15 | MTE3.1 | Neuro endocrine assessment after a childhood intracranial or suprasellar tumour |
| 17:15-18:15 | | Meet The Expert 4 Alexandra Trianti Hall
|
| 17:15 | MTE4.1 | The use of modern technologies to optimise diabetes care |
| 17:15-18:15 | | Yearbook of Paediatric Endocrinology 1 Chair(s): Juliane Léger (Paris, France) Christos Lambrakis Hall
|
| YB1.1 | Thyroid |
| YB1.2 | Adrenals |
| YB1.3 | Obesity and Weight Regulation |
| YB1.4 | Type 2 Diabetes, Metabolic Syndrome and Lipids |
| YB1.5 | Global Health for the Paediatric Endocrinologist |
| 18:30-20:00 | | Satellite Symposium Alexandra Trianti Hall
|
| 18:30-20:00 | | Satellite Symposium Nikos Skalkotas Hall
|
| 18:30-20:00 | | Satellite Symposium Dimitris Mitropoulos Hall
|
| 20:00-21:30 | | Informal ESPE Networking Event Exhibition Hall
|
Friday 28 September 2018 |
| 07:30-08:45 | | Registration open
|
| 08:00-08:30 | | Plenary 3 Chair(s): Bessie Spiliotis (Patras, Greece) & Martin Wabitsch (Ulm, Germany) Christos Lambrakis Hall
|
| 08:00 | PL3 | Clinical and molecular genetics of corticotroph pituitary tumors (Cushing's disease) |
| 08:30-09:30 | | Meet the Expert 1 MC3
|
| 08:30 | MTE1.2 | The role of Radiology in the diagnosis of skeletal dysplasias |
| 08:30-09:30 | | Meet The Expert 5 Banqueting Hall
|
| 08:30 | MTE5.1 | Reproductive function in CAH |
| 08:30-09:30 | | Meet The Expert 6 Alexandra Trianti Hall
|
| 08:30 | MTE6.1 | Management of Hypo & Hypercalcaemia |
| 08:30-09:30 | | Meet The Expert 7 Dimitris Mitropoulos Hall
|
| 08:30 | MTE7.1 | The management of a child with Prader-Willi syndrome: from infancy to adulthood |
| 08:30-09:30 | | Meet The Expert 8 Nikos Skalkotas Hall
|
| 08:30 | MTE8.1 | Psychology of childhood diabetes: How to motivate children and families with T1D |
| 08:30-09:30 | | Yearbook of Paediatric Endocrinology 2 Chair(s): Olaf Hiort (Lübeck, Germany) Christos Lambrakis Hall
|
| YB2.1 | Bone, Growth Plate and Mineral Metabolism |
| YB2.2 | Growth and Growth Factors |
| YB2.3 | Pituitary and Neuroendocrinology |
| YB2.4 | Puberty |
| YB2.5 | Antenatal and Neonatal Endocrinology |
| 09:30-11:00 | | ERN: The concept and scope of Endo-ERN Chair(s): Mehul T Dattani (London, UK) & Peter Clayton (Manchester, UK) Dimitris Mitropoulos Hall
|
| 09:30 | ERN1.1 | Introduction: The concept and scope of Endo-ERN |
| 09:55 | ERN1.2 | Patient advocacy in Endo-ERN: Adrenal |
| 10:05 | ERN1.3 | Patient advocacy in Endo-ERN:Men-1 and pituitary adenomas in childhood |
| 10:25 | ERN1.4 | CAH Transition: Optimisation |
| 10:45 | ERN1.5 | EuRRECa - European Registries For Rare Endocrine Conditions |
| 09:30-10:30 | | Free Communications 6 Chair(s): Elpida Viapapadopoulou (Athens, Greece) & Claude Marcus (Stockholm, Sweden) Fat, metabolism and obesity Nikos Skalkotas
|
| 09:30 | FC6.1 | Correlations between measures of adiposity across childhood and adolescence and the intestinal microbiota in 15-17 year-old children with a family history of obesity: preliminary findings from the QUALITY cohort. |
| 09:40 | FC6.2 | Impaired Brain Satiety Responses to a Meal in Children with Obesity. |
| 09:50 | FC6.3 | Role of PTEN in the proliferation and differentiation of preadipocytes. |
| 10:00 | FC6.4 | Identification of the first obesity-associated mutations in human mesoderm-specific transcript (MEST) result in protein overexpression, adipocyte hypertrophy and a reduction in adipocyte mitochondrial area. |
| 10:10 | FC6.5 | The role of adipocytes in childhood precursor Bcell lymphoblastic leukemia. |
| 10:20 | FC6.6 | MicroRNA-141 directly targets and inhibits sirtuins 1 gene expression and its elevation in obese subjects is responsible for reduced levels of sirtuin1 and the subsequent hepatic steatosis and insulin resistance. |
| 09:30-10:30 | | Free Communications 7 Chair(s): Indi Banerjee (Manchester, UK) & Michel Polak (Paris, France) Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) MC3
|
| 09:30 | FC7.1 | Expression and localisation of insulin, glucagon, amylin, pancreatic polypeptide and PDX-1 in pancreatic tissue of children with congenital hyperinsulinism. |
| 09:40 | FC7.2 | Enteroinsular hormone responses during Fasting, Oral Glucose Tolerance Test and Mixed Meal in children with hyperinsulinaemic hypoglycaemia. |
| 09:50 | FC7.3 | Diazoxide-induced pulmonary hypertension: UK multicentre retrospective study on the risk factors, monitoring approach and management recommendations. |
| 10:00 | FC7.4 | Altered substrate specificities and metabolite production by aromatase (CYP19A1) due to the R192H mutation. |
| 10:10 | FC7.5 | Thyroid hormone levels in cord blood are associated with fetal and neonatal growth. |
| 10:20 | FC7.6 | TSH-resistance and remaining low-T4 in former low-birthweight infants – a study in monozygotic twins with intra-twin birth-weight-differences. |
| 09:30-10:30 | | Free Communications 8 Chair(s): Paul-Martin Holterhuis (Kiel, Germany) & Ken McElreavey (Paris, France) Sex differentiation, gonads and gynaecology or sex endocrinology Christos Lambrakis Hall
|
| 09:30 | FC8.1 | Estrogen Receptor 2 Variant as a Novel Cause for Dysgenetic Ovaries. |
| 09:40 | FC8.2 | Partial restoration of biological effects of estrogen in a female with estrogen receptor α variant. |
| 09:50 | FC8.3 | Exomic sequencing uncovers novel genetic associations for Deciphering Developmental Disorders (DDD) Study participants with hypospadias, cardiovascular and neurodevelopmental abnormalities. |
| 10:00 | FC8.4 | STARD8, a novel candidate gene for 46,XY disorders of sex development. |
| 10:10 | FC8.5 | DEAH-box helicase 37defects (DXH37) deffects are a Novel Cause of 46,XY Gonadal Dysgenesis. |
| 10:20 | FC8.6 | The roles of steroids in gonadal development and maintenance – insights from a zebrafish model of androgen and cortisol deficiency. |
| 09:30-10:30 | | Free Communications 9 Chair(s): Ivo Jorge Arnhold (São Paulo, Brazil) & Ron Rosenfeld (Oregon, USA) Pituitary, neuroendocrinology and puberty 1 Banqueting Hall
|
| 09:30 | FC9.1 | Novel variants in the POU1F1 beta isoform are associated with isolated growth hormone deficiency and combined pituitary hormone deficiency. |
| 09:40 | FC9.2 | Contribution of Functionally Assessed GHRHR Mutations to Idiopathic Isolated Growth Hormone Deficiency in a Cohort of 312 Unrelated Patients. |
| 09:50 | FC9.3 | Mutations in MAGEL2 and L1CAM are associated with congenital hypopituitarism and arthrogryposis. |
| 10:00 | FC9.4 | Neuroendocrine Morbidity after Paediatric Craniopharyngioma: A Longitudinal Single Centre Analysis of 93 Patients Over 30 Years. |
| 10:10 | FC9.5 | National multidisciplinary decision-making guideline for children and young people (<19 years) with idiopathic thickened pituitary stalk and/or idiopathic central diabetes insipidus. |
| 10:20 | FC9.6 | National UK Guidelines For Screening, Multi-Disciplinary team Management And Long-Term Follow-Up Of Children and Young People (CYP) with Multiple Endocrine Neoplasia Type 1 (MEN1). |
| 09:30-11:00 | | Free Communications 10 Chair(s): Leo Dunkel (London, UK) & Pratik Shah (London, UK) Late Breaking Alexandra Trianti Hall
|
| 09:30 | FC10.1 | Burosumab Improved Rickets, Phosphate Metabolism, and Clinical Outcomes Compared to Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH) – A Randomized Controlled Phase 3 Study |
| 09:40 | FC10.2 | Efficacy and safety of once-weekly somapacitan in childhood growth hormone deficiency: results of a randomised open-label, controlled phase 2 trial |
| 09:50 | FC10.3 | Identification of the MAPK/ERK pathway as a novel therapeutic target in adamantinomatous craniopharyngioma |
| 10:00 | FC10.4 | Hypothalamus sparing surgery improves the outcome of patients with severe initial hypothalamic involvement of childhood craniopharyngioma: Results of the Prospective Multinational Trial KRANIOPHARYNGEOM 2007 |
| 10:10 | FC10.5 | A 5-year single-centre experience on the safety and efficacy of Sirolimus therapy used for the treatment of congenital hyperinsulinaemic hypoglycaemia |
| 10:20 | FC10.6 | Primary ovarian insufficiency incidence rate and etiology among Israeli adolescents between the years 2000-2016 – A multi-center study |
| 10:30 | RFC10.1 | Patients with GH Insensitivity and IGF-1 Resistance Harbour Copy Number Variants Causing a Silver-Russell-Like Phenotype |
| 10:35 | RFC10.2 | Non-inferiority clinical trial on gonadotropinversus pulsatile gonadotropin-releasing hormone infusion therapy in male adolescent patient withcongenital hypogonadotropic hypogonadism |
| 10:40 | RFC10.3 | Developmental regulation of obestatin and adropin in Prader-Willi syndrome and non-syndromic obesity: associations with weight, BMI-z, HOMA-IR, and lipid profile |
| 10:45 | RFC10.4 | Comparative analysis between immunoassay and tandem mass spectrometry for androgens before and after human recombinant gonadotrophin in children with genital ambiguity and 46,XY karyotype |
| 10:50 | RFC10.5 | Effects of birth weight on profiles of dried bloodamino-acids and acylcarnitines |
| 10:55 | RFC10.6 | Effect of the current treatment of X-Linked Hypophosphatemia during growth on the development of osteoarticular lesions in the Hyp mouse model |
| 10:30-11:00 | | Rapid Free Communications 6 Chair(s): Elpida Viapapadopoulou (Athens, Greece) & & Claude Marcus (Stockholm, Sweden) Fat, metabolism and obesity Nikos Skalkotas
|
| 10:30 | RFC6.1 | Allelic variation in key fitness genes is linked with increased severity of obesity in overweight/obese youth. |
| 10:35 | RFC6.2 | IGF-I at four months associates to visceral and subcutaneous adipose tissue at 7 years of age. |
| 10:40 | RFC6.3 | Effect of the Melanocortin-4 Receptor Agonist, Setmelanotide, on Obesity and Hyperphagia in Individuals Affected by Bardet-Biedl Syndrome. |
| 10:45 | RFC6.4 | Functionality and phenotypic characteristics of mutations in the human leptin receptor. |
| 10:50 | RFC6.5 | High-throughput untargeted plasma metabolomics unravels gender dimorphic metabolic trajectories in naturally conceived and ICSI prepubertal children. |
| 10:55 | RFC6.6 | Effects of Cherry's extract on increased osteclastogenesis in obese children. |
| 10:30-11:00 | | Rapid Free Communications 7 Chair(s): Indi Banerjee (Manchester, UK) & Pratik Shah (London, UK) Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) MC3
|
| 10:30 | RFC7.1 | Next generation sequencing results in 142 patients with congenital hyperinsulinism. |
| 10:35 | RFC7.2 | Outcomes of a quality improvement project integrating Continuous Glucose Monitoring Systems into the routine management of neonatal hypoglycaemia. |
| 10:40 | RFC7.3 | Central venous cathether-associated thrombosis in children with congenital hyperinsulinism. |
| 10:45 | RFC7.4 | Expression of MIR-576-5p in umbilical cord as a novel biomarker for the identification of catch-up growth in small-for-gestational-age infants. |
| 10:50 | RFC7.5 | Alteration of Renal Corticosteroid Signaling Pathways in Preterm Infants: Neonatal Adaptation and Developmental Programming of Hypertension. |
| 10:55 | RFC7.6 | Assessment of Pituitary Stalk Anatomy by T2 DRIVE without Gadolinium in Pituitary Diseases. |
| 10:30-11:00 | | Rapid Free Communications 8 Chair(s): Paul-Martin Holterhuis (Kiel, Germany) Sex differentiation, gonads and gynaecology or sex endocrinology Christos Lambrakis Hall
|
| 10:30 | RFC8.1 | Male fertility genes located in Y-chromosomal regions display differential mRNA profiles in response to GnRH treatment of cryptorchidism-dependent infertility. |
| 10:35 | RFC8.2 | High Mobility Group Box 1 (HMGB1) is increased in adolescents with Polycystic Ovarian Syndrome (PCOS) and decreases after treatment with myo-inositol in combination with α-lipoic acid (MYO+ALA). |
| 10:40 | RFC8.3 | Pharmacological treatment of adolescent Polycystic Ovary Syndrome (PCOS) according to the 2018 International Evidence-Based Guideline for the Assessment and Management of PCOS. |
| 10:45 | RFC8.4 | Establishing age, sex, and method related reference ranges for anogenital distance - a marker of in utero androgen action. |
| 10:50 | RFC8.5 | Latest progress in tissue engineered urethral regeneration. From rabbit to dog, a step from human clinical trial for surgical treatment of VSD (Variation of Sex Development). |
| 10:55 | RFC8.6 | Metabolic profile of young adult transgender persons who started gender affirming treatment in their adolescence. |
| 10:30-11:00 | | Rapid Free Communications 9 Chair(s): Ivo Jorge Arnhold (São Paulo, Brazil) & Ron Rosenfeld (Oregon, USA) Pituitary, neuroendocrinology and puberty 1 Banqueting Hall
|
| 10:30 | RFC9.1 | Clinical and genetic features of central precocious puberty associated with complex phenotypes. |
| 10:35 | RFC9.2 | Novel variant in GNRHR gene regulatory region in a pedigree with maternally inherited precocious puberty. |
| 10:40 | RFC9.3 | What is the best parameter to decide the initial dose of depot leuprolide acetate in girls with idiopathic central precocious puberty? |
| 10:45 | RFC9.4 | REplacement of MAle mini-Puberty in neonates and children with micropenis and cryptorchidism due to hypogonadotropic hypogonadism. Results of the “REMAP” study ISRCTN13007297. |
| 10:50 | RFC9.5 | Non-isolated central precocious puberty: prevalence of brain lesions and other associated disorders. |
| 10:55 | RFC9.6 | Can neuroimagine predict endocrine morbidity in congenital hypothalamo-pituitary (H-P) disorders? |
| 11:00-11:30 | | Refreshment Break, Posters & Exhibition
|
| 11:30-12:00 | | ESPE AWARDS Chair(s): Agnès Linglart (Paris, France) ESPE Research Award Supported by Pfizer
|
| 12:00-12:30 | | Plenary 4 Chair(s): Francesco Chiarelli (Chieti, Italy) & Moshe Phillip (Petah Tikva, Israel) Christos Lambrakis Hall
|
| 12:00 | PL4 | Prediction, Identification, and Treatment of Early Stage Type 1 Diabetes |
| 12:30-13:00 | | ESPE AWARDS Chair(s): Evangelia Charmandari (Athens, Greece) ESPE Hormone Research in Paediatrics Prizes; IFCAH-ESPE award; ESPE Outstanding Clinician Award; ESPE International Outstanding Clinician Award Supported by S. Karger AG & the International Fund for Research on Congenital Adrenal Hyperplasia
|
| 13:00-14:30 | | Lunch, Posters & Exhibition
|
| 14:30-16:00 | | Symposium 4 Chair(s): Maria Karantza (Athens, Greece) & Rasa Verkauskiene (Kaunas, Lithuania) Management of late effects of cancer therapy Banqueting Hall
|
| S4.1 | Late reproductive sequelae following treatment of childhood cancer and options for fertility in females |
| S4.2 | Diagnosis and Treatment of Hypogonadism in girls after cancer therapy |
| S4.3 | Diagnosis and Treatment of Hypogonadism in boys after cancer therapy |
| 14:30-16:00 | | Symposium 5 Chair(s): Zdeněk Šumník (Prague, Czech Republic) & Assimina Galli-Tsinopolou (Thessaloniki, Greece) ISPAD - ESPE Preventing late complications in children with T1D Christos Lambrakis Hall
|
| S5.1 | Prognosis of diabetic children today: Global perspective |
| S5.2 | Re-defining targets for optimal T1D control |
| S5.3 | Beta cell replacement therapy |
| 14:30-16:00 | | Symposium 6 Chair(s): Nils Krone (Sheffield, UK) & Christa Flück (Bern, Switzerland) Molecular mechanisms of tissue sensitivity to glucocorticoids: potential clinical implications Dimitris Mitropoulos Hall
|
| S6.1 | The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease |
| S6.2 | Immune regulation by glucocortcoids |
| S6.3 | Circadian regulation of glucocorticoid secretion |
| 14:30-16:30 | | ESPE Working Group on European Society of Paediatric Endocrine Nurses (ESPEN) Chair(s): Liesbeth Lambrechts (Utrecht, The Netherlands) & Kate Davies (London, UK) Paediatric Endocrine Nursing Competencies MC3
|
| WG7.1 | Advanced anthropometry in GH-treated patients |
| WG7.2 | Next generation nursing: Genomic competencies for pediatric endocrine nurses |
| WG7.3 | Managing Adrenal Insufficiency |
| 14:30-16:00 | | Controversy 2 Chair(s): Jan-Maarten Wit (Leiden, The Netherlands) To prime or not to prime? Alexandra Trianti Hall
|
| 14:30 | CON2.1 | PRO - To prime or not to prime? |
| 15:15 | CON2.2 | CON - To prime or not to prime? |
| 14:30-16:00 | | Novel Advances 1 Chair(s): Nicolas de Roux (Paris, France) The clinical relevance of metabolomics; genomic engineering - CRISP-R/Cas9 and its many applications Nikos Skalkotas Hall
|
| NA1.1 | The clinical relevance of metabolomics |
| NA1.2 | The relevance of genomic engineering – to include CRISP-R |
| 16:00-16:30 | | Plenary 5 Chair(s): Evangelia Charmandari (Athens, Greece) & Constantine Stratakis (Rockville, USA) Christos Lambrakis Hall
|
| PL5 | Dynamic control of tissue glucocorticoids – lessons for optimising replacement therapy |
| 16:30-17:00 | | Refreshment Break, Posters & Exhibition
|
| 17:00-18:30 | | Satellite Symposia Alexandra Trianti Hall
|
| 17:00-18:30 | | Satellite Symposia Banqueting Hall
|
| 17:00-18:30 | | Satellite Symposia Dimitris Mitropoulos Hall
|
| 18:30-20:00 | | ESPE Business Meeting Banqueting Hall
|
Saturday 29 September 2018 |
| 07:30-08:45 | | Registration
|
| 08:00-09:00 | | Meet The Expert 2 MC3
|
| MTE2.2 | Endocrine complications in Thalassemia |
| 08:00-09:00 | | Meet the Expert 3 Banqueting Hall
|
| MTE3.2 | Neuro endocrine assessment after a childhood intracranial or suprasellar tumour |
| 08:00-09:00 | | Meet The Expert 5 Alexandra Trianti Hall
|
| MTE5.2 | Reproductive function in CAH |
| 08:00-09:00 | | Meet The Expert 6 Dimitris Mitropoulos Hall
|
| 08:00 | MTE6.2 | Management of Hypo & Hypercalcaemia |
| 08:00-09:00 | | Yearbook of Paediatric Endocrinology 3 Chair(s): Sandro Loche (Cagliari, Sardinia, Italy) Christos Lambrakis Hall
|
| YB3.1 | Editor's Choice |
| YB3.2 | Gender dysphoria and Disorders of Sex Development |
| YB3.3 | Type 1 Diabetes |
| YB3.4 | Oncology and Chronic Disease |
| YB3.5 | The Year in Science & Medicine |
| 08:00-08:45 | | Satellite Symposia Nikos Skalkotas Hall
|
| 09:00-10:00 | | Free Communications 11 Chair(s): Dionysios Chrysis (Rio, Greece) & Evelien Gevers (London, UK) Bone, growth plate and mineral metabolism 2 Christos Lambrakis Hall
|
| 09:00 | FC11.1 | Successful immune tolerance induction in the first case of neutralizing antibody mediated loss of efficacy of asfotase alfa treatment in hypophosphatasia. |
| 09:10 | FC11.2 | Elevated phosphate levels inhibit skeletal muscle cell differentiation in vitro. |
| 09:20 | FC11.3 | Evidence for effects of FGF2 aptamer in an achondroplasia mice model and an in vitrochondrocyte differentiation system using patient-derived iPS cells. |
| 09:30 | FC11.4 | Using patient derived induced pluripotent stem cells to model multiple epiphyseal dysplasia. |
| 09:40 | FC11.5 | A recurrent 6-bp intronic deletion in NESP55 with reduced penetrance in pseudohypoparathyroidism type 1b. |
| 09:50 | FC11.6 | Management of severe, protracted hypocalcaemia in patients undergoing thymus transplantation in a tertiary centre: a 10-year experience. |
| 09:00-10:00 | | Free Communications 12 Chair(s): Fergus Cameron (Victoria, Australia) & Maria Papagianni (Thessaloniki, Greece) Diabetes and Insulin 2 Banqueting Hall
|
| 09:00 | FC12.1 | Continuous Glucose Monitoring Profiles in Healthy Non-Diabetic Children and Adolescents: A Multicenter Prospective Study. |
| 09:10 | FC12.2 | Apoptosis and oxidative stress markers during the Oral Glucose Tolerance Test (OGTT). |
| 09:20 | FC12.3 | Impact of insulin sensitivity and β-cell function on the development of impaired glucose tolerance (IGT) in obese European children and adolescents. |
| 09:30 | FC12.4 | How does thiol/disulphide homeostasis change in children with type 1 diabetesmellitus? |
| 09:40 | FC12.5 | Effect of Homocysteine-Lowering Therapy on Diabetic Nephropathy in Children and Adolescents with Type 1 Diabetes. |
| 09:50 | FC12.6 | Persistent beneficial effects of metformin in children and adolescents with type 1 diabetes: Adelaide metformin randomized controlled trial follow up. |
| 09:00-10:00 | | Free Communications 13 Chair(s): Ana Claudia Latronico (São Paulo, Brazil) & Taneli Raivio (Helsinki, Finland) Pituitary, neuroendocrinology and puberty 2 Dimitris Mitropoulos
|
| 09:00 | FC13.1 | Molecular screening of genes associated with central precocious puberty. |
| 09:10 | FC13.2 | Ablation of AgRP Neurons Decreases Survival In Activity-Based Anorexia Model. |
| 09:20 | FC13.3 | Role of GnRH neuronal migration and development in Self-Limited Delayed Puberty. |
| 09:30 | FC13.4 | The Kallman syndrome gene product is specifically expressed in ACTH-expressing cells and dysplays sexual dimorphism expression in human fetal pituitary. |
| 09:40 | FC13.5 | Study of the serum kisspeptin level in healthy and hypogonadotropic boys. |
| 09:50 | FC13.6 | Teamwork saves lives: how pediatric multidisciplinary care can prevent ‘unexplained deaths’ in adults with Prader-Willi syndrome. |
| 09:00-10:00 | | Free Communications 14 Chair(s): Stefan Riedl (Vienna, Austria) & Nicos Skordis (Nicosia, Cyprus) Multisystem endocrine disorders MC3
|
| 09:00 | FC14.1 | Awareness & Participation In Rare Disease Registries Within The European Reference Network On Rare Endocrine Conditions (Endo-ERN). |
| 09:10 | FC14.2 | National UK guidelines for the clinical assessment, diagnosis, treatment and follow-up of children and young people (CYP) under 19 years of age with phaeochromocytoma (PCC) and paraganglioma (PGL) - On behalf of the UK Paediatric Phaeochromocytoma and Paraganglioma Guideline Development Group (GDG). |
| 09:20 | FC14.3 | Regulation of Salt, Sugar and Sex Steroids in Humans by Genetic Variations in NADPH Cytochrome P450 Oxidoreductase (POR) identified in 1000 genome samples. |
| 09:30 | FC14.4 | Glucocorticoid deficiency causes differentially dysregulated oxidative stress depending on the steroidogenic defects. |
| 09:40 | FC14.5 | Pubertal females produce an enhanced interferon-alpha, anti-viral response compared to males, which is associated with X chromosome number, and not sex hormones. |
| 09:50 | FC14.6 | Sex differences in autoimmune disease: testosterone is associated with a decrease in expression of key anti-viral genes during puberty, which may decrease the risk of autoimmunity in males. |
| 09:00-10:00 | | Free Communications 15 Chair(s): Wolfgang Högler (Birmingham, UK) and Philippe Backeljauw (Ohio, USA) Growth and syndromes (to include Turner syndrome) Nikos Skalkotas Hall
|
| 09:00 | FC15.1 | The diagnostic yield of a targeted next generation sequencing panel in children with short stature of undefined aetiology. |
| 09:10 | FC15.2 | Effects of caloric restriction during gestation on the methylome of offspring's adipose tissue and reversibility of such effects by metformin in a swine model. |
| 09:20 | FC15.3 | Methylation of the C19MC microrna locus in the placenta: A mechanism whereby maternal body size links to that of the child. |
| 09:30 | FC15.4 | The metabolic profile associated with RASopathies. |
| 09:40 | FC15.5 | Utility of BDNF and MMP-1 as markers of cardiometabolic risk in Turner syndrome girls. |
| 09:50 | FC15.6 | Vosoritide for Children with Achondroplasia: A 30 Month Update from an Ongoing Phase 2 Clinical Trial. |
| 09:00-10:00 | | How Do I... Chair(s): Alan Rogol (Charlottesville, USA) Session 2 Alexandra Trianti Hall
|
| 09:00 | HDI2.1 | ...Manage a child with a thickened pituitary stalk |
| 09:20 | HDI2.2 | ...Manage a child with physical disabilities who has a low bone mineral density |
| 09:40 | HDI2.3 | ...Investigate a clinically euthyroid child with a thyroid nodule |
| 10:00-10:30 | | Rapid Free Communications 11 Chair(s): Dionysios Chrysis (Rio, Greece) & Evelien Gevers (London, UK) Bone, growth plate and mineral metabolism 2 Christos Lambrakis Hall
|
| 10:00 | RFC11.1 | Diagnosis and management of pseudohypoparathyroidism and related disorders: First international consensus statement. |
| 10:05 | RFC11.2 | Nationwide hypophyosphatemic rickets study. |
| 10:10 | RFC11.3 | Increased levels of bone formation and resorption markers in patients with hypophosphatemic rickets. |
| 10:15 | RFC11.4 | A new form of Anhidrotic Ectodermal Dysplasia with Immunodeficiency caused by abolished Store-Operated Ca2+ Entry. |
| 10:20 | RFC11.5 | The Determinants Of Skeletal Fragility In Children With Type 1 Diabetes Mellitus. |
| 10:25 | RFC11.6 | Reference Values of Automated Bone Age and Bone Health Index for Mexican children and adolescents. |
| 10:00-10:30 | | Rapid Free Communications 12 Chair(s): Reinhard Holl (Ulm, Germany) & Maria Papagianni (Thessaloniki, Greece) Diabetes and Insulin Session 2 Banqueting Hall
|
| 10:00 | RFC12.1 | Use of acid-suppressive medications during infancy and early childhood and its association with type 1 diabetes. |
| 10:05 | RFC12.2 | Bone mineral density is increased in 276 Danish children and adolescents with Type-1-Diabetes. |
| 10:10 | RFC12.3 | Barriers and sources of support for the performance of physical activity inpediatric type 1 diabetes. |
| 10:15 | RFC12.4 | Use of telemonitoring via a mobile device app reduces HbA1c in type 1 diabetic children and adolescents. |
| 10:20 | RFC12.5 | Insulin gene promoter methylation status in Greek children and adolescents with Type 1 Diabetes. |
| 10:25 | RFC12.6 | AMGLIDIA, a suspension of glibenclamide for patients with neonatal diabetes, long term data on efficiency and tolerance. |
| 10:00-10:30 | | Rapid Free Communications 13 Chair(s): Ana Claudia Latronico (São Paulo, Brazil) & Taneli Raivio (Helsinki, Finland) Pituitary, neuroendocrinology and puberty 2 Dimitris Mitropoulos
|
| 10:00 | RFC13.1 | Risk of long-term endocrine sequelae in survivors of progressing childhood optic pathway glioma (OPG) treated by upfront chemotherapy. Preliminary analyses of 102 subjects from the French multicentric BB-SFOP registry. |
| 10:05 | RFC13.2 | Growth outcomes and near adult height of children with congenital GH deficiency (GHD) due to abnormal pituitary development: data from a prospective, multinational observational study. |
| 10:10 | RFC13.3 | Circulating MKRN3, Kisspeptin and IGF-1 levels in girls during the clinical onset of puberty. |
| 10:15 | RFC13.4 | Gain in predicted adult height using the combination of an LHRH analogue and an aromatase inhibitor in early maturing girls with compromised growth for 2 yrs or until the age of 11 is maintained and further improved by aromatase inhibitor monotherapy. Results on final height of the “GAIL” study ISRCTN11469487. |
| 10:20 | RFC13.5 | Pubertal voice break: Temporal relation of secondary sexual characteristics in healthy boys. |
| 10:25 | RFC13.6 | Close correlation between salivary and blood steroids in normal boys: Salivary testosterone best characterizes male puberty. |
| 10:00-10:30 | | Rapid Free Communications 14 Chair(s): Stefan Riedl (Vienna, Austria) & Nicos Skordis (Nicosia, Cyprus) Multisystem endocrine disorders MC3
|
| 10:00 | RFC14.1 | Psychometric and Psycho-social Profile of Children and Adolescent Survivors of Pediatric Cancer. |
| 10:05 | RFC14.2 | British Society for Paediatric Endocrinology and Diabetes peer review of specialised paediatric endocrinology services in the UK - Evaluation of the outcomes. |
| 10:10 | RFC14.3 | Dysregulated glucose homeostasis in Congenital Central Hypoventilation Syndrome. |
| 10:15 | RFC14.4 | A novel germline DICER1 mutation in a girl with multinodular goiter and ovarian Sertoli-Leydig cell tumor. |
| 10:20 | RFC14.5 | Natural course of MEN type 2B syndrome; a Dutch single-center cohort. |
| 10:25 | RFC14.6 | Identification of epithelial sodium channel (ENaC) in endometrial pipelle biopsy samples. |
| 10:00-10:30 | | Rapid Free Communications 15 Chair(s): Wolfgang Högler (Birmingham, UK) Growth and syndromes (to include Turner syndrome) Nikos Skalkotas Hall
|
| 10:00 | RFC15.1 | Diagnosis of Silver-Russell syndrome in patients with chromosome 14q32.2 imprinted region disruption: phenotypic and molecular analysis. |
| 10:05 | RFC15.2 | Molecular and clinical analyses of two UPD(16)mat patients detected by screening of 94 Silver-Russell syndrome patients without known etiology. |
| 10:10 | RFC15.3 | Multiple pituitary hormone deficiencies and early onset obesity in two siblings with a mutation in the MAGEL2-gene.Evidence for an important regulatory function of the MAGEL2-gene in the hypothalamic-pituitary hormone pathways. |
| 10:15 | RFC15.4 | Characteristics, effectiveness and safety data from clinically relevant subgroups of patients with severeprimary IGF-I deficiency (SPIGFD): results from the European Increlex® Growth Forum Database (EU-IGFD) registry. |
| 10:20 | RFC15.5 | Effect of Adjusting for Tanner Stage Age on Short and Tall Stature Prevalence in US Youths. |
| 10:25 | RFC15.6 | Latest results from PATRO Children, a multi-centre, non-interventional study of the long-term safety and efficacy of Omnitrope® in children requiring growth hormone treatment. |
| 10:30-11:00 | | Refreshment Break, Posters & Exhibition
|
| 11:00-11:30 | | Plenary 6 Chair(s): Jesús Argente (Madrid, Spain) & Tsutoma Ogata (Tokyo, Japan) Christos Lambrakis Hall
|
| PL6 | Personalized treatments using gut microbiome and clinical data |
| 11:30-12:00 | | ESPE AWARDS Chair(s): Peter Clayton (Manchester, UK) Andrea Prader Prize Supported by Pfizer Christos Lambrakis Hall
|
| 12:00-12:30 | | Plenary 7 Chair(s): Carlo Acerini (Cambridge, UK) & David Dunger (Cambridge, UK) Christos Lambrakis Hall
|
| PL7 | New curative treatment strategies for Type 1 diabetes |
| 12:30-14:00 | | Lunch, Posters & Exhibition
|
| 12:45-13:45 | | Satellite Symposia
|
| 13:45-14:45 | | ESPE AWARDS Chair(s): Eirini Kostopoulou (Athens, Greece) & Rodolfo Rey (Buenos Aires, Argentina) Young Investigators Session Supported by Pfizer Christos Lambrakis Hall
|
| YI1.1 | Cellular reprogramming to understand Cell fate Choice During Human Sex-Determination |
| YI1.2 | Adipokines and genetic markers of childhood obesity and insulin resistance |
| YI1.3 | A qualitative study investigating family concerns of girls with CAH born with virilisation managed with and without surgery |
| 14:00-15:00 | | Novel Advances 2 Chair(s): Wieland Kiess (Leipzig, Germany) Cell engineering for treatment of diabetes Nikos Skalkotas Hall
|
| NA2.1 | Stem cells as a source of beta cells |
| NA2.2 | Regenerating beta cells |
| 14:00-15:00 | | Meet The Expert 4 Alexandra Trianti Hall
|
| MTE4.2 | The use of modern technologies to optimise diabetes care |
| 14:00-15:00 | | Meet The Expert 7 Banqueting Hall
|
| 14:00 | MTE7.2 | The management of a child with Prader-Willi syndrome: from infancy to adulthood |
| 14:00-15:00 | | Meet The Expert 8 Dimitris Mitropoulos Hall
|
| 14:00 | MTE8.2 | Psychology of childhood diabetes: How to motivate children and families with T1D |
| 14:45-15:30 | | ESPE Activities Chair(s): Faisal Ahmed (Glasgow, UK) & Rasa Verkauskiene (Kaunas, Lithuania) How can ESPE help shape my career? Christos Lambrakis Hall
|
| AC1.1 | The ESPE roadmap to a career in academic paediatric endocrinology |
| AC1.2 | Grants and Fellowships for Scientific Development |
| AC1.3 | ESPE Schools: An interactive learning environment |
| AC1.4 | Clinical Fellowship: Specialised training opportunities in Paediatric Endocrinology |
| AC1.5 | PETCA: A graduate’s experience |
| 15:00-15:30 | | Refreshment Break, Posters & Exhibition
|
| 15:30-17:00 | | Symposium 7 Chair(s): Dov Tiosano (Haifa, Israel) & Faisal Ahmed (Glasgow, UK) Bone Symposium Banqueting Hall
|
| 15:30 | S7.1 | X-linked Hypophosphataemic Rickets: Disease and Treatment |
| 16:00 | S7.2 | Hypophosphatasia: Disease and Treatment |
| 16:30 | S7.3 | Achondroplasia-New hopes |
| 15:30-17:00 | | Symposium 8 Chair(s): Heiko Krude (Berlin, Germany) & Catherine Dacou-Voutetakis (Athens, Greece) Thyroid disorders Christos Lambrakis Hall
|
| 15:30 | S8.1 | Thyroid hormone transporter defects |
| 16:00 | S8.2 | Central Hypothyroidism – an Update |
| 16:30 | S8.3 | Paediatric differentiated thyroid cancer: outcome and long term effects |
| 15:30-17:00 | | Symposium 9 Chair(s): Mohamad Maghnie (Genoa, Italy) & Gabriele Haeusler (Vienna, Austria) Novel advances in endocrine imaging Dimitris Mitropoulos Hall
|
| 15:30 | S9.3 | Novel techniques in diagnostics of bone strength |
| 16:00 | S9.1 | Visualisation of pancreatic beta cells |
| 16:30 | S9.2 | Novel CNS Imaging techniques |
| 15:30-17:00 | | Symposium 10 Chair(s): Julie Chowen (Madrid, Spain) & Antje Körner (Leipzig, Germany) Paediatric obesity: Mechanisms and novel treatment Alexandra Trianti Hall
|
| 15:30 | S10.1 | Key learnings from European studies on obesity prevention |
| 16:00 | S10.2 | Functional Leptin Deficiency Disorders and Treatment |
| 16:30 | S10.3 | MC4R agonists in the treatment of monogenic disorders of obesity |
| 17:00-17:30 | | ESPE AWARDS Chair(s): Peter Clayton (Manchester, UK) ESPE International Award & ESPE President Poster Award Christos Lambrakis Hall
|
| 17:30-18:00 | | Plenary 8 Chair(s): Annette Grueters-Kieslich (Berlin, Germany) & Cheri Deal (Montréal, Canada) Christos Lambrakis Hall
|
| 17:30 | PL8 | Turner syndrome: new insights from prenatal genomics and transcriptomics |
| 18:00-18:15 | | Closing Ceremony Christos Lambrakis Hall
|
| 20:00-21:45 | | ESPE Evening
|